个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase 1 study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Song Yuqin[1] ; Jin Zhengming[2] ; Li Zhi-Ming[3] ; Liu Yanyan[4] ; Li Lanfang[5] ; He Chuan[6] ; Su Hang[7] ; Zhou Hui[8] ; Li Kunyan[9] ; Hao Siguo[10] ; Zuo Xuelan[11] ; Wu Jianyuan[12] ; Li Dengju[13] ; Wu Meng[1] ; Sun Xiuhua[14] ; Qi Junyuan[15] ; Cai Zhen[16] ; Li Zengjun[17] ; Li Yijing[18] ; Huang Yanhua[18] ; Shen Jie[18] ; Xiao Zhenyu[18] ; Zhu Jun[1] ;
机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China [2]Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China [3]Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [4]Lymphatic Comprehensive Internal Medicine Ward, Henan Cancer Hospital, Zhengzhou, China [5]Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China [6]Department of Hematopathology, West China Hospital Sichuan University, Chengdu, China [7]Department of Lymphoma, The Fifth Medical Center of the People’s Liberation Army General Hospital, Beijing, China [8]Department of Lymphoma & Hematology (Children’s Tumor Center), Hunan Cancer [9]Early Clinical Trial Center, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China [10]Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China [11]Department of Hematopathology, Zhongnan Hospital of Wuhan University, Wuhan, China [12]Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, China [13]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [14]Department of Lymphoma and Head and Neck Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China [15]Good Clinical Practice Ward, Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China [16]Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China [17]Department of Lymphology and Hematology, Cancer Hospital Affiliated to Shandong First Medical University, Jinan, China [18]Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China
出处：
DOI： 10.1158/1078-0432.CCR-23-2582
ISSN：

关键词： peripheral T-cell lymphoma EZH2 SHR2554

摘要：
Patients with peripheral T-cell lymphomas (PTCLs) in the relapsed or refractory (r/r) setting have only a limited number of therapies available, and the prognosis is extremely poor. SHR2554 is an oral inhibitor against EZH2, a rational therapeutic target for lymphomas.This was a multicenter, 2-part, phase 1 study of SHR2554 in r/r mature lymphoid neoplasms. In part I, 350 mg twice daily was established as the recommended phase 2 dose (RP2D) based on the findings during dose-escalation and expansion; subsequently, selected lymphoma subtypes were recruited in clinical expansion cohorts to receive SHR2554 at RP2D. Here, we provide an in-depth assessment of SHR2554 at RP2D in subpopulation with r/r PTCLs.Totally, 28 patients were included for analysis (17 angioimmunoblastic T-cell lymphoma and 11 not otherwise specified). 18 (64%) patients had received ≥2 lines of previous anti-cancer therapies. The objective response rate was 61% (95% CI 41-78). Responses were still ongoing in 59% (10/17) of the responders; estimated median duration of response was 12.3 months (95% CI 7.4-not reached). Median progression-free survival was 11.1 months (95% CI 5.3-22.0), and 12-month overall survival rate was 92% (95% CI 72-98). The most common grade 3 or 4 treatment-related adverse events were decreased platelet count (nine [32%]) as well as decreased white blood cell count, decreased neutrophil count, and anemia (four [14%] for each). No treatment-related deaths were reported.This extended follow-up analysis further supports SHR2554 as a therapeutic opportunity for patients with r/r PTCLs.

基金：
This study was funded by Jiangsu Hengrui Pharmaceuticals.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
通讯作者：
推荐引用方式(GB/T 7714)：
Song Yuqin,Jin Zhengming,Li Zhi-Ming,et al.Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase 1 study[J].CLINICAL CANCER RESEARCH.2024,30(7):1248-1255.doi:10.1158/1078-0432.CCR-23-2582.
APA：
Song Yuqin,Jin Zhengming,Li Zhi-Ming,Liu Yanyan,Li Lanfang...&Zhu Jun.(2024).Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase 1 study.CLINICAL CANCER RESEARCH,30,(7)
MLA：
Song Yuqin,et al."Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase 1 study".CLINICAL CANCER RESEARCH 30..7(2024):1248-1255

相关文献

[1]Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China [2]Use of Complete Blood Count for Prognostic Evaluation of Peripheral T-Cell Lymphoma [3]Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL) [4]Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma [5]Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified [6]Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China [7]CXCL13、CD10和bcl-6在血管免疫母细胞性T细胞淋巴瘤的诊断及鉴别诊断中的作用 [8]Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting [9]Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: A multicentre real-world analysis [10]A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号